Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Chronic-Phase 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1

Interventions

fludarabine phosphate 4Mycophenolic Acid 4Cyclophosphamide 4Antilymphocyte Serum 3Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Cyclosporine 2Cord Blood Stem Cell Transplantation 2Busulfan 2sargramostim 1olverembatinib 1danusertib 1Whole-Body Irradiation 1Rituximab 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Methylprednisolone 1Methotrexate 1Levofloxacin 1Lenalidomide 1Ketamine 1Flow Cytometry 1Filgrastim 1Cefepime 1Carboplatin 1CT-P10 1Analgesia 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid, Accelerated Phase × olverembatinib × Clear all
NCT03883100 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Ascentage Pharma Group Inc.

Phase 2 Unknown
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡